Mucormycosis

Mucormycosis is an aggressive opportunistic fungal infection caused by fungi belonging to the order Mucorales, affecting birds and many other animal species with often devastating consequences. This rapidly progressive infection occurs primarily in severely immunocompromised hosts and is characterized by tissue invasion, blood vessel involvement, and necrosis that can spread quickly through affected organs. While relatively uncommon in companion birds compared to some other mycoses, mucormycosis represents one of the most challenging fungal infections to treat due to its aggressive nature and the inherent resistance of causative organisms to many antifungal agents. Recognition of this serious condition is important for avian veterinarians and bird owners alike.

The fungi responsible for mucormycosis include several genera within the order Mucorales, most commonly Rhizopus, Mucor, Rhizomucor, and Lichtheimia (formerly Absidia). These ubiquitous organisms exist in soil, decaying vegetation, and organic matter throughout the world, where they play important roles in decomposition processes. The fungi produce abundant spores that become airborne readily, making exposure essentially unavoidable in normal environments. Despite this ubiquitous exposure, clinical infection rarely occurs in healthy hosts, as these fungi have limited pathogenic capability in the face of normal immune defenses. The organisms' ability to invade blood vessels and cause thrombosis with subsequent tissue necrosis distinguishes mucormycosis from many other fungal infections.

The impact of mucormycosis on affected birds is typically severe, reflecting both the aggressive nature of the infection and the underlying immunocompromise that permitted infection to develop. The hallmark angioinvasive nature of these fungi leads to blood vessel destruction, thrombosis, and tissue death that can progress rapidly through affected organs. Different clinical forms exist depending on the portal of entry, including rhinocerebral, pulmonary, gastrointestinal, cutaneous, and disseminated mucormycosis. The infection can spread from a primary focus to involve multiple organ systems. Quality of life deteriorates rapidly in affected birds, and without aggressive intervention, the condition is frequently fatal.

Treatment of mucormycosis requires urgent, aggressive intervention combining antifungal therapy with surgical debridement of necrotic tissue when feasible. The limited number of antifungal agents with reliable activity against Mucorales organisms complicates treatment, with amphotericin B formulations typically representing first-line therapy. Even with appropriate treatment, outcomes are often poor, particularly for disseminated infection or when diagnosis is delayed. Prevention focuses on maintaining immune competence through optimal husbandry, nutrition, and prompt treatment of any illness. Early recognition and intervention offer the best chance of survival in this challenging infection.

The primary causes of mucormycosis are fungi belonging to the order Mucorales, a diverse group of organisms with cosmopolitan distribution in soil and decaying organic matter. The genera most frequently associated with avian infections include Rhizopus, particularly Rhizopus arrhizus and related species, which causes the majority of human and animal mucormycosis cases. Mucor species, Rhizomucor pusillus, Lichtheimia species, and Cunninghamella bertholletiae also produce disease. These fungi are characterized by broad, sparsely septate or aseptate hyphae that can be identified microscopically in tissue sections. The organisms grow rapidly on culture media, typically producing characteristic fluffy colonies within days. Their rapid growth reflects the aggressive behavior seen in clinical infections.

Environmental exposure to Mucorales fungi occurs constantly as these organisms exist ubiquitously in soil, compost, decaying plant material, and many foods. The fungi produce abundant sporangiospores that become airborne easily and survive for extended periods in dry conditions. Inhalation of spores represents the primary route of exposure for pulmonary and rhinocerebral infections. Ingestion of contaminated food leads to gastrointestinal mucormycosis. Cutaneous infection develops through direct inoculation of spores into damaged skin. Despite the universality of exposure, clinical infection is rare, occurring almost exclusively when profound host immune defects permit fungal establishment and invasion. Environmental factors that increase exposure include proximity to agricultural operations, composting facilities, and construction activities that disturb soil.

Profound immunosuppression represents the critical factor determining whether environmental exposure results in clinical mucormycosis. The level of immune compromise required for mucormycosis typically exceeds that permitting other opportunistic fungal infections, reflecting the organism's limited pathogenic capability in the face of functioning immunity. Conditions predisposing to mucormycosis include severe prolonged stress, malnutrition leading to profound immune compromise, advanced systemic illness, extended antibiotic therapy disrupting normal flora, and in some cases, iron overload conditions that favor fungal growth. Young birds with immature immune systems facing additional stressors and debilitated birds with multiple concurrent health issues face particular risk. Any condition producing profound, sustained immunosuppression can predispose to this opportunistic infection.

Specific risk factors identified in avian mucormycosis cases provide insight into susceptible populations. Captive waterfowl appear overrepresented in reported cases, possibly related to dietary factors, environmental moisture, or species-specific susceptibility. Penguins in zoological collections have experienced mucormycosis outbreaks associated with environmental contamination. Raptors in rehabilitation experiencing severe stress and compromised nutrition have developed mucormycosis. Birds with prolonged gastrointestinal disease potentially have increased susceptibility to the gastrointestinal form through compromised mucosal barriers. Iron storage disorders, though not well characterized in birds, might increase risk as they do in mammals. Understanding risk factors helps identify birds requiring particular vigilance.

The pathogenesis of mucormycosis involves tissue invasion and angioinvasion that distinguish this infection from most other fungal diseases. Following establishment at the portal of entry, fungal hyphae extend through tissues, causing direct damage and eliciting inflammatory responses. The hallmark feature of mucormycosis is angioinvasion, where hyphae penetrate blood vessel walls, causing thrombosis and tissue infarction. This vascular involvement leads to the characteristic tissue necrosis with black eschar formation seen in affected areas. The combination of direct fungal damage, inflammatory response, and ischemic necrosis produces rapidly progressive tissue destruction. In disseminated disease, spread occurs through blood vessels, carrying fungal elements to distant sites. The rapid progression reflects both aggressive fungal growth and the severe underlying immunocompromise that permits infection.

Early warning signs of mucormycosis may be subtle initially despite the ultimately aggressive nature of this infection. The earliest symptoms often relate to the underlying immunocompromising condition rather than the fungal infection itself. Birds may show nonspecific signs including mild lethargy, decreased appetite, and general malaise that could be attributed to many causes. Early localized infection may produce mild discomfort or swelling at the affected site before dramatic tissue changes develop. Because mucormycosis primarily affects severely compromised hosts already showing signs of illness, the onset of fungal infection may be difficult to distinguish from progression of underlying disease. The rapid progression characteristic of mucormycosis means that early subtle signs quickly evolve into more obvious disease manifestations.

Respiratory mucormycosis manifests with symptoms of lower respiratory infection that may progress with alarming rapidity. Affected birds show increasing respiratory rate and effort, open-mouth breathing, and obvious respiratory distress. Nasal discharge may occur with upper respiratory involvement. Voice changes or loss of vocalization can indicate laryngeal or tracheal involvement. The progression from initial respiratory symptoms to severe distress may occur over days rather than the weeks typical of some other respiratory mycoses. Hemoptysis may occur if pulmonary blood vessels are affected. Respiratory mucormycosis carries grave prognosis due to the vital nature of the affected organ system.

Gastrointestinal mucormycosis produces symptoms reflecting intestinal involvement and potential perforation. Affected birds show decreased appetite progressing to anorexia. Vomiting or regurgitation may occur. Abdominal distension develops as the intestinal tract becomes affected. Changes in droppings including diarrhea or absence of feces indicate intestinal dysfunction. Melena or hematochezia may occur with intestinal ulceration. The abdomen may become painful on palpation. Systemic signs of peritonitis develop if intestinal perforation occurs. Gastrointestinal mucormycosis may follow ingestion of heavily contaminated food and carries poor prognosis due to difficulty of treating intestinal fungal invasion.

Cutaneous mucormycosis presents with distinctive local tissue changes that may evolve rapidly. Initial skin lesions appear as areas of redness, swelling, or induration at sites of previous trauma or other skin breaks. The lesions rapidly progress to develop central necrosis with characteristic black eschar formation as angioinvasion causes tissue death. Surrounding tissue shows progressive involvement as fungal invasion extends beyond the initial focus. The affected area may have malodorous discharge as necrosis develops. Pain behavior may be evident depending on lesion location. Without treatment, cutaneous lesions continue to expand and may disseminate to internal organs.

Disseminated mucormycosis involves multiple organ systems and produces severe systemic illness. Affected birds show profound lethargy progressing to obtundation. Anorexia and weight loss progress rapidly. Multiple body systems may show signs of involvement simultaneously or sequentially. Neurological signs may develop with central nervous system involvement. Fever or hypothermia reflects systemic infection and failing homeostasis. Collapse and inability to maintain normal posture indicate critical illness. The appearance of new lesions in different body areas suggests hematogenous dissemination. Disseminated mucormycosis has very poor prognosis, with survival unlikely despite aggressive treatment.

Emergency symptoms requiring immediate veterinary attention include rapidly progressive respiratory distress, expanding areas of tissue necrosis, signs of acute abdomen suggesting intestinal perforation, neurological deterioration, and septic appearance with collapse. Any bird with suspected or confirmed mucormycosis showing rapid deterioration requires emergency evaluation. The aggressive nature of this infection means that delays of even hours can significantly affect outcomes. Owners of birds with known risk factors should be alert to any concerning changes and seek immediate veterinary care for evaluation.

Initial examination of birds with suspected mucormycosis involves rapid assessment combining history, physical findings, and risk factor evaluation. The veterinarian assesses for predisposing conditions that might have permitted this opportunistic infection. Physical examination documents the extent of any visible lesions, with particular attention to the characteristic necrotic tissue changes of mucormycosis. Respiratory function assessment is critical for suspected pulmonary involvement. Abdominal palpation may reveal masses or pain suggesting gastrointestinal disease. The bird's overall condition and stability determine the urgency of diagnostic procedures and treatment initiation. Given the aggressive nature of mucormycosis, rapid diagnosis is essential for optimal outcomes.

Laboratory diagnosis of mucormycosis relies primarily on demonstration of characteristic fungal elements in tissue and culture confirmation. Cytological examination of lesion samples or tissue aspirates may reveal the distinctive broad, sparsely septate or aseptate hyphae with right-angle branching that characterize Mucorales fungi, allowing rapid presumptive diagnosis. Biopsy of affected tissue with histopathological examination provides both fungal identification and documentation of tissue invasion, a key diagnostic feature. Special stains including GMS and PAS highlight fungal elements. Culture of tissue samples on appropriate fungal media typically yields rapid growth of the causative organism within days, allowing genus and species identification. Molecular methods including PCR may provide rapid confirmation when available.

Imaging studies help assess disease extent and guide treatment planning. Radiography may reveal pulmonary infiltrates, cavitary lesions, or abdominal masses depending on disease location. The aggressive, destructive nature of mucormycosis may produce characteristic radiographic findings. Advanced imaging including computed tomography provides detailed assessment of lesion extent and vascular involvement. Imaging findings help stage disease and identify areas requiring surgical attention. Serial imaging during treatment monitors response, though clinical improvement often precedes radiographic improvement.

Differential diagnosis for mucormycosis includes other fungal infections, bacterial diseases, and neoplastic conditions producing similar presentations. Aspergillosis causes respiratory and disseminated disease but typically progresses more slowly and shows different histopathological features. Fusariosis can produce aggressive infection in immunocompromised hosts. Bacterial infections including necrotizing soft tissue infections may produce similar local tissue destruction. Neoplastic conditions may cause masses or tissue destruction resembling fungal granulomas. The distinctive histopathological appearance of Mucorales organisms with tissue invasion and angioinvasion helps distinguish mucormycosis from these alternatives. Rapid differentiation guides antifungal selection, as Mucorales organisms show different susceptibility patterns than other fungi.

Emergency treatment of mucormycosis begins immediately upon diagnosis or strong clinical suspicion, as delays significantly worsen outcomes in this rapidly progressive infection. Stabilization of critically ill patients includes respiratory support for birds in distress, fluid therapy for compromised cardiovascular function, and temperature support for thermoregulation. Antifungal therapy should begin as soon as possible without waiting for culture confirmation if clinical suspicion is high. The urgency of treatment cannot be overstated given the aggressive nature of this infection. Simultaneously, evaluation for underlying conditions requiring correction should begin. Any immediately life-threatening complications require concurrent management.

Medical management of mucormycosis relies primarily on amphotericin B formulations, which remain the cornerstone of therapy despite significant limitations. Conventional amphotericin B deoxycholate provides effective antifungal activity but carries substantial nephrotoxicity risk requiring careful monitoring. Lipid formulations of amphotericin B offer improved safety profiles allowing higher doses and longer treatment duration. Dosing follows established avian protocols, with adjustments based on response and toxicity monitoring. Posaconazole has emerged as an alternative or adjunct therapy with activity against Mucorales and improved safety compared to amphotericin B. Isavuconazole provides another azole option with anti-Mucorales activity. Combination therapy may offer synergistic benefits in severe cases. Treatment duration extends for weeks to months depending on response and disease extent.

Surgical intervention plays a critical role in mucormycosis management and often determines outcome when combined with medical therapy. Surgical debridement removes necrotic tissue containing fungal burden that antifungal medications cannot adequately penetrate. Early, aggressive surgical debridement improves survival rates significantly in human mucormycosis, and similar principles apply to avian cases. For cutaneous lesions, wide excision with margins extending into healthy tissue addresses both visible and microscopic disease. Debridement may need to be repeated if progression continues. The extent of surgical intervention depends on lesion location and patient stability. In some anatomical locations, radical surgery may not be feasible, limiting treatment options.

Supportive care addresses the multiple ways mucormycosis and its treatment affect patient wellbeing. Nutritional support ensures adequate intake during a period when appetite is typically poor and metabolic demands are high. Fluid therapy maintains hydration and renal function, particularly important when nephrotoxic antifungal agents are used. Temperature support assists thermoregulation in debilitated patients. Pain management improves comfort and quality of life. Treatment of secondary bacterial infections addresses complications of tissue necrosis. Correction of underlying conditions that permitted infection remains essential for treatment success. The intensive supportive care needs of mucormycosis patients often require hospitalization during the acute phase.

Monitoring during treatment guides therapy adjustment and assesses response. Frequent clinical assessment tracks lesion progression or improvement and overall patient status. Laboratory monitoring includes renal function assessment for patients receiving amphotericin B. Serial imaging evaluates changes in lesion extent. Culture results and sensitivities may guide modification of empirical therapy. The lack of standardized biomarkers for mucormycosis makes clinical assessment the primary guide to treatment response. Failure to improve despite apparently appropriate therapy prompts reassessment of diagnosis, consideration of resistant organisms, and evaluation of surgical options.

Treatment decisions for mucormycosis involve difficult considerations given the severity of disease and challenges of treatment. The prognosis is guarded to poor in most cases, particularly for disseminated disease. Treatment is intensive, expensive, and carries its own risks including antifungal toxicity and surgical complications. The severe underlying immunocompromise that permitted infection affects both treatment tolerance and ultimate outcome. Honest discussion of realistic expectations helps owners make informed decisions about pursuing aggressive treatment versus comfort care. Quality of life considerations weigh heavily when treatment burden is substantial and outcomes uncertain.

Recovery from mucormycosis, when achievable, follows a prolonged course reflecting the aggressive nature of the infection and the intensive treatment required. Initial stabilization may occur within days to one to two weeks as antifungal therapy and surgical intervention control active infection. However, complete recovery extends over weeks to months of continued treatment and rehabilitation. The resolution of necrotic lesions occurs gradually as dead tissue separates and healthy tissue regenerates. Systemic recovery follows control of local disease. Throughout recovery, continued vigilance for recurrence or progression is essential, as treatment failures occur despite apparently appropriate therapy.

Post-treatment care focuses on wound healing, preventing recurrence, and addressing underlying conditions. Wounds from surgical debridement require ongoing management until complete healing. Continued antifungal therapy extends beyond clinical resolution to prevent relapse from residual infection. Nutritional support promotes tissue repair and immune function restoration. Environmental management reduces re-exposure to fungal spores, though complete elimination is impossible. Correction of any modifiable factors that contributed to immunosuppression reduces recurrence risk. Close monitoring for any signs of returning infection allows early intervention if needed.

Prognosis for mucormycosis is generally guarded to poor, with outcomes depending heavily on disease extent, promptness of diagnosis and treatment, underlying host factors, and anatomical location. Localized cutaneous infections diagnosed early and treated aggressively with combined medical and surgical therapy offer the best outcomes, though even these cases carry significant risk. Pulmonary and disseminated disease have poor prognosis despite aggressive treatment. The degree of underlying immunocompromise significantly affects both treatment response and recurrence risk. Survival rates in avian mucormycosis are not well documented but appear lower than for some other fungal infections reflecting the aggressive nature of this disease.

Long-term outlook for mucormycosis survivors depends on residual damage from infection, ongoing management of underlying conditions, and recurrence risk. Birds surviving mucormycosis may have permanent functional deficits depending on which tissues were affected and the extent of surgical debridement required. Continued vulnerability to opportunistic infections persists if underlying immunocompromise cannot be corrected. The psychological impact on owners of managing such a serious illness affects long-term care compliance. Regular veterinary monitoring remains important for detecting any recurrence early. Despite the challenges, some birds do survive mucormycosis with aggressive treatment and go on to have acceptable quality of life.

Environmental prevention of mucormycosis focuses on minimizing exposure intensity while recognizing that complete elimination of Mucorales spores from the environment is impossible. Reducing organic debris that supports fungal growth decreases local spore concentrations. Proper ventilation reduces airborne spore accumulation in enclosed spaces. Avoiding housing birds near composting operations, hay storage, or other sources of heavy fungal contamination limits exposure. Regular cleaning removes accumulating organic material that could support fungal growth. Food storage should prevent spoilage that allows fungal proliferation. While environmental management cannot eliminate exposure, reducing intensity helps prevent the overwhelming inoculum that might produce infection in susceptible hosts.

Preventing immunosuppression represents the most important preventive measure, as mucormycosis almost exclusively affects severely compromised hosts. Optimal nutrition maintains immune competence through complete, balanced diets appropriate to the species. Stress minimization through appropriate housing, social grouping, and environmental stability supports immune function. Prompt treatment of any illness prevents the chronic debilitation that produces profound immunosuppression. Avoiding prolonged antibiotic courses when possible maintains normal flora. Treatment of any identified immunocompromising conditions reduces susceptibility to opportunistic infections. For birds with unavoidable risk factors, heightened vigilance allows early intervention if infection develops.

Quarantine protocols for new arrivals provide opportunity to assess health status before introduction to established collections. The quarantine period allows observation for signs of illness that might indicate immunocompromise predisposing to opportunistic infections. Veterinary examination during quarantine evaluates overall health. Birds from high-risk backgrounds warrant careful assessment before joining collections containing potentially vulnerable individuals. Equipment and supplies remain separate between quarantine and main collection to prevent pathogen transfer.

Health maintenance through regular veterinary care supports immune function and allows early detection of problems. Wellness examinations provide opportunity for health assessment and identification of developing issues before they produce profound compromise. Prompt attention to any illness prevents progression to severe debilitation. Nutritional assessment ensures dietary adequacy. Environmental review identifies any factors that might compromise health. Building a relationship with an avian veterinarian before emergencies arise ensures access to knowledgeable care when needed.

Early recognition of mucormycosis risk in susceptible individuals allows heightened vigilance and rapid response if infection develops. Understanding which birds face particular risk based on concurrent conditions or other factors guides monitoring intensity. Awareness of early symptoms prompts rapid veterinary consultation when concerns arise. For high-risk birds, even subtle changes may warrant evaluation. The aggressive nature of mucormycosis means that early intervention offers the best chance of successful treatment.

Daily management of birds being treated for mucormycosis requires intensive attention to medication administration, wound care, and monitoring. Antifungal medications must be given exactly as prescribed, often multiple times daily for some formulations. Birds receiving amphotericin B may require injectable administration. Surgical wounds need regular care following veterinary guidance. Daily assessment documents response to treatment, with particular attention to lesion status, respiratory function, appetite, and overall condition. Recording detailed observations provides valuable information for frequent veterinary communications. The intensive care requirements of mucormycosis treatment often exceed what can be accomplished at home during the acute phase, potentially requiring hospitalization.

Home environment during recovery from mucormycosis should minimize stress while facilitating monitoring and care. Housing setup should allow easy observation and access for medication administration and wound care. Temperature maintenance in a warm range supports thermoregulation in debilitated patients. Air quality optimization benefits respiratory function. Reducing environmental complexity simplifies cleaning while the bird is immunocompromised. Food and water should be easily accessible with modifications as needed for weakened patients. Separation from other birds may be advisable for intensive individual monitoring and to protect immunocompromised patients from additional infectious challenges.

Quality of life considerations become paramount during intensive mucormycosis treatment. The treatment burden is substantial, and balancing aggressive intervention against patient comfort requires ongoing assessment. Birds should receive appropriate pain management for comfort. Mental stimulation appropriate to energy level supports psychological wellbeing. Social interaction with owners, within the constraints of treatment requirements, provides emotional support. Recognizing when treatment is causing more suffering than benefit guides difficult decisions about treatment continuation. The goal is always the bird's wellbeing, whether through curative treatment or compassionate comfort care.

Ongoing monitoring during mucormycosis treatment is intensive, often requiring frequent veterinary contact. Hospitalization during the acute phase allows constant professional monitoring. Following discharge, frequent rechecks assess treatment response. Laboratory monitoring tracks organ function and treatment effects. Any concerning changes require immediate communication with the veterinary team. The aggressive nature of mucormycosis means that delays in recognizing deterioration can be devastating. Close collaboration between owner and veterinary team throughout treatment optimizes chances for successful outcome.

Caregiver support is essential during the challenging experience of managing mucormycosis in a companion bird. The intensity of care requirements, uncertain prognosis, and difficult treatment decisions create significant emotional stress. Open communication with the veterinary team about prognosis, treatment options, and quality of life helps owners make informed decisions. Financial strain from intensive treatment may affect decision-making. Support from family, friends, or bird owner communities helps manage emotional burden. Recognizing when continuation of aggressive treatment may not be in the bird's best interest, and supporting humane end-of-life decisions when appropriate, represents an important aspect of compassionate care.

Waterfowl appear overrepresented in reported cases of avian mucormycosis, with ducks, geese, and swans among frequently affected groups. The reasons for waterfowl susceptibility may include environmental factors, dietary components, or species-specific immune characteristics. Captive waterfowl in zoological collections have experienced mucormycosis outbreaks associated with environmental contamination or dietary issues. Wild waterfowl in rehabilitation may develop mucormycosis due to stress and compromised nutrition. The moist environments typical of waterfowl housing may support fungal growth. Aspergillosis is also common in waterfowl, suggesting possible general susceptibility to fungal infections. Management of waterfowl collections should include awareness of mucormycosis risk.

Penguins in zoological collections have experienced notable mucormycosis outbreaks, with several facilities reporting cases or clusters over the years. The stress of captivity, suboptimal environmental conditions, and potential nutritional issues may contribute to susceptibility. Air conditioning systems in penguin exhibits have been implicated as sources of fungal contamination in some outbreaks. The difficulty of providing optimal conditions for these specialized birds may create chronic stress affecting immune function. Penguin facilities should implement environmental monitoring and optimize husbandry to reduce opportunistic infection risk.

Other bird species develop mucormycosis primarily when profoundly immunocompromised by concurrent conditions. Raptors in rehabilitation facilities experiencing severe stress and nutritional compromise have developed mucormycosis. Psittacines with advanced systemic illness occasionally develop this opportunistic infection. Birds with prolonged antibiotic therapy disrupting normal flora may face increased risk. Any species can potentially be affected when immune function is sufficiently compromised. The commonality among affected birds is severe underlying immunosuppression rather than species-specific susceptibility, though certain species may face elevated risk due to environmental or husbandry factors.

Aspergillosis represents the most commonly diagnosed invasive mycosis in birds and shares the characteristic of primarily affecting immunocompromised hosts. Both infections can produce respiratory and disseminated disease in susceptible individuals. However, aspergillosis typically progresses more slowly than mucormycosis and responds to a broader range of antifungal medications. The histopathological appearance differs, with Aspergillus showing narrow, septate, acute-angle branching hyphae compared to the broad, sparsely septate, right-angle branching hyphae of Mucorales. Both infections may occur in the same high-risk patients, and dual infection is possible. Distinguishing the causative organism through histopathology and culture is essential for optimal antifungal selection.

Other invasive fungal infections requiring differentiation from mucormycosis include fusariosis, candidiasis, and other opportunistic mycoses. Fusariosis can produce aggressive infection in immunocompromised hosts but typically responds to different antifungal agents than mucormycosis. Invasive candidiasis usually has different anatomical distribution, primarily affecting the gastrointestinal tract. Cryptococcosis causes systemic disease with particular central nervous system tropism. Accurate diagnosis through appropriate testing ensures proper treatment, as antifungal susceptibility varies significantly among these different fungal groups.

Complications of mucormycosis extend the disease impact and reflect the aggressive tissue-destructive nature of this infection. Tissue necrosis from angioinvasion causes permanent loss of affected structures, with functional consequences depending on anatomical location. Secondary bacterial infection of necrotic tissue is common and may contribute to systemic illness. Hemorrhage from blood vessel destruction can be immediately life-threatening. Perforation of hollow organs including intestine leads to peritonitis. Dissemination from a primary focus to distant sites produces multiorgan failure. The underlying immunocompromising conditions that permitted mucormycosis to develop persist and may lead to other opportunistic infections or complications. Even survivors may have permanent disability from tissue loss sustained during the infection.